<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00030524</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000069174</org_study_id>
    <secondary_id>UTHSC-0015011185</secondary_id>
    <secondary_id>SACI-IDD-01-01</secondary_id>
    <secondary_id>NCI-3753</secondary_id>
    <nct_id>NCT00030524</nct_id>
  </id_info>
  <brief_title>ZD 1839 in Treating Patients With Locally Advanced or Metastatic Colorectal Cancer</brief_title>
  <official_title>A Phase II Clinical, Biological and Pharmacological Study of ZD1839 in Patients With Advanced Colorectal Carcinoma Refractory to 5-Fluorouracil (5-FU) and Irinotecan Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Texas Health Science Center at San Antonio</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>The University of Texas Health Science Center at San Antonio</source>
  <brief_summary>
    <textblock>
      RATIONALE: Biological therapies such as ZD 1839 may interfere with the growth of tumor cells&#xD;
      and slow the growth of colorectal cancer.&#xD;
&#xD;
      PURPOSE: Phase II trial to study the effectiveness of ZD 1839 in treating patients who have&#xD;
      locally advanced or metastatic colorectal cancer that has not responded to chemotherapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the progression-free rate at 16 weeks, response rate, time to treatment&#xD;
           failure, and survival of patients treated with gefitinib for locally advanced or&#xD;
           metastatic colorectal adenocarcinoma that is refractory to fluorouracil, irinotecan, and&#xD;
           capecitabine.&#xD;
&#xD;
        -  Correlate the pharmacodynamic effects of this drug with indices of clinical benefit&#xD;
           (e.g., tumor growth inhibition, time to tumor progression, and survival) in these&#xD;
           patients.&#xD;
&#xD;
        -  Determine whether the status of epidermal growth factor receptor activation and&#xD;
           signaling are predictive of clinical outcome in patients treated with this drug.&#xD;
&#xD;
      OUTLINE: This is a multicenter study.&#xD;
&#xD;
      Patients receive oral gefitinib once daily. Treatment continues every 28 days in the absence&#xD;
      of disease progression or unacceptable toxicity.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 18-46 patients will be accrued for this study within 5-12&#xD;
      months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2002</start_date>
  <completion_date type="Actual">September 2003</completion_date>
  <primary_completion_date type="Actual">September 2003</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <condition>Colorectal Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gefitinib</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically or cytologically confirmed colorectal adenocarcinoma&#xD;
&#xD;
               -  Metastatic or locally advanced disease&#xD;
&#xD;
               -  Not amenable to curative therapy&#xD;
&#xD;
          -  Documentation of disease progression within the past 6 months&#xD;
&#xD;
          -  Previously treated with fluoropyrimidine- and irinotecan-based chemotherapy (including&#xD;
             capecitabine) administered either concurrently (no more than 2 regimens) or&#xD;
             sequentially (no more than 3 regimens) for advanced disease&#xD;
&#xD;
          -  At least 1 unidimensionally measurable lesion&#xD;
&#xD;
               -  At least 20 mm by conventional techniques OR at least 10 mm by spiral CT scan&#xD;
&#xD;
          -  No known brain metastases&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  ECOG 0-2 OR&#xD;
&#xD;
          -  Karnofsky 60-100%&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  More than 12 weeks&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Absolute neutrophil count at least 1,500/mm^3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin no greater than 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  AST/ALT no greater than 3 times ULN (5 times ULN if liver metastasis present)&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine no greater than 1.5 times ULN OR&#xD;
&#xD;
          -  Creatinine clearance at least 60 mL/min&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  No symptomatic congestive heart failure&#xD;
&#xD;
          -  No unstable angina pectoris&#xD;
&#xD;
          -  No cardiac arrhythmia&#xD;
&#xD;
        Ophthalmic:&#xD;
&#xD;
          -  No significant ophthalmic conditions, including:&#xD;
&#xD;
               -  Severe dry-eye syndrome&#xD;
&#xD;
               -  Keratoconjunctivitis sicca&#xD;
&#xD;
               -  Sjogren's syndrome&#xD;
&#xD;
               -  Severe-exposure keratopathy&#xD;
&#xD;
               -  Disorders that may increase the risk for epithelium-related complications (e.g.,&#xD;
                  bullous keratopathy, aniridia, severe chemical burns, or neutrophilic keratitis)&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Able to take oral gefitinib&#xD;
&#xD;
          -  No other uncontrolled concurrent illness&#xD;
&#xD;
          -  No ongoing or active infection&#xD;
&#xD;
          -  No psychiatric illness or social situation that would preclude study participation&#xD;
&#xD;
          -  No prior gastrointestinal disorders (e.g., malabsorption syndrome)&#xD;
&#xD;
          -  No prior allergic reactions attributed to compounds of similar chemical or biological&#xD;
             composition to gefitinib&#xD;
&#xD;
          -  No other prior malignancy except carcinoma in situ of the cervix, nonmelanoma skin&#xD;
             cancer, or other cancer from which the patient has been free of evident disease for&#xD;
             more than 5 years and/or has less than a 20-30% estimated likelihood of recurrence&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 30 days since prior chemotherapy and recovered&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  No prior gastric resection&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No other prior therapy for advanced disease&#xD;
&#xD;
          -  No concurrent combination antiretroviral therapy for HIV-positive patients&#xD;
&#xD;
          -  No other concurrent investigational or commercial agents or therapies for the&#xD;
             malignancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chris H. Takimoto, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>The University of Texas Health Science Center at San Antonio</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institute for Drug Development</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Health Science Center at San Antonio</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78284-7811</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2012</verification_date>
  <study_first_submitted>February 14, 2002</study_first_submitted>
  <study_first_submitted_qc>May 6, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 7, 2003</study_first_posted>
  <last_update_submitted>October 26, 2012</last_update_submitted>
  <last_update_submitted_qc>October 26, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 30, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage III colon cancer</keyword>
  <keyword>stage IV colon cancer</keyword>
  <keyword>stage III rectal cancer</keyword>
  <keyword>stage IV rectal cancer</keyword>
  <keyword>recurrent colon cancer</keyword>
  <keyword>recurrent rectal cancer</keyword>
  <keyword>adenocarcinoma of the colon</keyword>
  <keyword>adenocarcinoma of the rectum</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gefitinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

